CGEN

#3025
Compugen Ltd. - Ordinary Shares
2.6 3 USD
-5.40%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
2.63
2.63
Range Annuel
1.32
3.24
Changement quotidien
-5.40%
Changement Mensuel
+0.38%
Evolution sur 6 mois
+67.52%
Changement Annuel
+69.68%
Clôture Précédente
2.7 8
Open
2.6 3
Low
2.6 3
High
2.6 3
Volume
11
Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques
Trimestriel Annuel
  • Market Capitalization 248.67 M
  • Employee 75
  • Founded 1993
  • CEO Anat Cohen-Dayag
  • Website www.cgen.com
  • Headquarter Israel
  • FIGI UNKNOWN
  • Industry Biotechnologies
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
4.03
ratio cours/chiffre d'affaires
1.97

Compugen Ltd. - Ordinary Shares

Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors.

Nouvelles